| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Tibet Cheezheng Tibetan Medicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.68 |
| 52 Week High | CN¥26.99 |
| 52 Week Low | CN¥16.27 |
| Beta | 0.63 |
| 1 Month Change | 6.28% |
| 3 Month Change | 11.56% |
| 1 Year Change | -15.63% |
| 3 Year Change | -10.36% |
| 5 Year Change | 2.00% |
| Change since IPO | 47.97% |
Recent News & Updates
Shareholder Returns
| 2287 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 6.2% | 0.8% | -0.4% |
| 1Y | -15.6% | -13.4% | -14.4% |
Return vs Industry: 002287 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 002287 underperformed the CN Market which returned -14.4% over the past year.
Price Volatility
| 2287 volatility | |
|---|---|
| 2287 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002287's share price has been volatile over the past 3 months.
Volatility Over Time: 002287's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 3,091 | Kailie Liu | www.cheezheng.com.cn |
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China. It provides products in the areas of orthopedics, neurology, dermatology, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, and cerebrovascular sectors.
Tibet Cheezheng Tibetan Medicine Co., Ltd. Fundamentals Summary
| 2287 fundamental statistics | |
|---|---|
| Market cap | CN¥12.02b |
| Earnings (TTM) | CN¥581.20m |
| Revenue (TTM) | CN¥2.05b |
20.7x
P/E Ratio5.9x
P/S RatioIs 2287 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2287 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.05b |
| Cost of Revenue | CN¥324.70m |
| Gross Profit | CN¥1.72b |
| Other Expenses | CN¥1.14b |
| Earnings | CN¥581.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 27, 2024
| Earnings per share (EPS) | 1.10 |
| Gross Margin | 84.12% |
| Net Profit Margin | 28.42% |
| Debt/Equity Ratio | 40.4% |
How did 2287 perform over the long term?
See historical performance and comparison